Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
-leading research in several fields. Notably, the groundbreaking discovery of the CRISPR-Cas9 gene-editing tool, which was awarded the Nobel Prize in Chemistry, was made here. At Umeå University, everything
-
for hematological and solid cancers. Your position The successful candidate will have the opportunity to work with cutting-edge experimental methods, including CRISPR-Cas9, single-cell RNA and ATAC sequencing
-
solid cancers. Your position The successful candidate will have the opportunity to work with cutting-edge experimental methods, including CRISPR-Cas9, single-cell RNA and ATAC sequencing, advanced high
-
-omics approaches, CRISPR-based functional genomics, and in vivo leukemia models to elucidate how chromatin alterations drive gene dysregulation and therapeutic resistance in pediatric acute myeloid
-
. The specific goal of this work is to unravel the molecular mechanisms of blood cell development using state-of-the-art technologies such as CRISPR screens, proteomics, and multi-omics approaches. About you: You
-
College of Chemistry and Molecular Engineering, Peking University | Ireland, | Ireland | about 14 hours ago
Four-year (48 months) Research Scientist (senior Postdoc level) position: Where: The Charles Institute of Dermatology (https://www.ucd.ie/charles/ ), School of Medicine (https://www.ucd.ie/medicine
-
approaches for hematological and solid cancers. The successful candidate will have the opportunity to work with cutting-edge experimental methods, including CRISPR-Cas9, single-cell RNA and ATAC sequencing
-
, thermodynamics of solvation shells, constant‑pH simulation methods, Markovian thermodynamics, as well as functional mechanisms of the ribosome, fatty acid synthase, CRISPR/Cas or intrinsically disordered proteins
-
of the Clelland lab is to develop novel therapies for neurodegenerative diseases including dementias and ALS. Projects are focused on basic mechanisms of disease and CRISPR gene editing in iPSCs, and iPSC-derived
-
therapies including CRISPR/Cas systems and antisense oligonucleotides for rare disease including Muscular Dystrophies. Our multidisciplinary group is dedicated to advancing biomedical research and developing